NKGen Biotech, Inc. (NASDAQ:NKGNW) Short Interest Down 89.7% in December
by Doug Wharley · The Cerbat GemNKGen Biotech, Inc. (NASDAQ:NKGNW – Get Free Report) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 1,700 shares, a decrease of 89.7% from the November 30th total of 16,500 shares. Based on an average daily trading volume, of 12,800 shares, the short-interest ratio is currently 0.1 days.
NKGen Biotech Stock Performance
Shares of NKGNW stock remained flat at $0.10 during mid-day trading on Friday. The company’s stock had a trading volume of 28,091 shares, compared to its average volume of 18,433. The firm’s 50-day moving average price is $0.05 and its two-hundred day moving average price is $0.07. NKGen Biotech has a 12 month low of $0.02 and a 12 month high of $0.29.
About NKGen Biotech
NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.
Read More
- Five stocks we like better than NKGen Biotech
- How to Use the MarketBeat Stock Screener
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- How AI Implementation Could Help MongoDB Roar Back in 2025
- The Basics of Support and Resistance
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?